Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, FVT

Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference


SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 1:20 p.m. EDT.  The conference is being held in a virtual format. 

A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. For more information, visit www.herontx.com.

Forward-Looking Statements 

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

David Szekeres
Chief Legal, Business and Administrative Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4447

SOURCE Heron Therapeutics, Inc.


These press releases may also interest you

at 21:05
TransAlta Declares Dividends
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

at 21:00
Omdia forecasts strong recovery in large-area display market for 2024, driven by sporting events and innovative production strategies
Research from Omdia's newly released Large Area Display Market Tracker 4Q23 has found shipments of large-area displays (all displays above 9inches), including both LCD and OLED, are forecasted to increase by 7.4% year-over-year (YoY) in units and...

at 20:56
FHU Announces New Computer Engineering Program, Launching Fall of 2024
Freed-Hardeman University will offer a new computer engineering program in the fall of 2024, providing students with the opportunity to enter a first cohort for a Bachelor of Science in engineering...

at 20:55
Quorum Announces Q4 and Year End 2023 Results
Quorum Information Technologies Inc. ("Quorum"), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original Equipment Manufacturers ("OEMs") rely on for their operations,...

at 20:16
Evolution Equity Partners Raises $1.1 Billion and Doubles Down on UK and EU Cybersecurity Investment
Evolution Equity Partners announced the final closing of Evolution Technology Fund III, LP on April 16th, 2024, and total capital commitments of $ 1.1 Billion to back visionary entrepreneurs building next generation...

More news about Science and technology...


News published on and distributed by: